Description: Discuss how the reinsurance can be utilized to manage the risk profile of the company. Potentially we can use a case or two to demonstrate the usage of reinsurance.

Description: The post COVID-19 period exhibited a fast-changing capital market with higher interest rates, uncertain monetary policies, and revaluation of asset classes. At the same time, regulators introduced changes to reward better risk management, such as the scenario-based approach for reserving under Bermuda regulatory framework. For life reinsurers, while new opportunities arising from these changes, challenges also exist to be able to adjust reinsurance portfolios and ALM strategies appropriately. A holistic modeling framework can assist companies better position themselves in front of these challenges and other potential future unknowns. In particular, a well-designed stochastic and dynamic modeling framework enables the quantifications of such probabilities and potential impacts.

Description: "COVID-19 and excess mortality: an actuarial study – Camille Delbrouck, Aon Benfield, Belgium, Jennifer Alonso-García, Department of Mathematics, Université Libre de Bruxelles, Belgium, ARC Centre of Excellence in Population Ageing Research (CEPAR), UNSW Sydney, Australia Netspar, The Netherlands How did COVID-19 change the dependence structure across major causes of death – Han Li, Ph.D., Associate Professor, Centre for Actuarial Studies | Faculty of Business and Economics, The University of Melbourne, Victoria, Australia"

Description: Navigate a perspective on the process of developing estimates and projections of mortality rates, based on a Living to 100 paper by the teacher. Discover the approach and considerations an actuary (or others) can take to develop a mortality rate assumption for five time periods. It will describe techniques to estimate historical mortality rates from which to project future mortality rates.

Description: Getting people to think beyond retirement about future care needs and how they will be paid for is critical for a healthy aging plan. However, most people avoid the topic and make rushed decisions when finding long-term care services. Hear from experts in this advisory field explain what a successful plan looks like and what it takes to get people to plan ahead.

Description: A panel of leading reinsurance executivesprovide perspective on topics to include market capacity, cell and gene therapy, COVID-19's impact on results, syndication arrangements, mergers and acquisitions, and how reinsurers view a variety of risk transfer opportunities.

Description: The Asian insurance landscape is undergoing significant change, with Japan experiencing a surge in reinsurance activity. This webcast will explore the factors driving this growth and provide insights into the current state and future direction of the Japanese reinsurance market. We'll delve into the unique characteristics of the Japanese market, examining the specific reinsurance needs of Japanese life insurers and how partnerships with US and offshore reinsurers are evolving. Looking ahead, we'll analyze the expected trajectory of the market, including the types of business and products likely to see increased demand. We'll also discuss how emerging economic factors and regulatory changes will shape future needs and the competitive landscape. Join us to gain valuable insights into this dynamic market and its future potential.

Description: IFRS 17 will be effective as of 1 Jan 2023 and provide opportunities as well as challenges to both Direct Writers and Reinsurers across the insurance industry. If the new framework is not fully understood, an implementation can elevate the risk of problems in financial reporting, product development, investment management and more. The transition to IFRS provides an opportunity for companies to optimize the financial position of the enterprise by implementing mitigating strategies to reduce the risks and challenges that IFRS brings to the table.

Description: This session will address the risk management, reserving and capital issues associated with index-linked annuities including financial reporting considerations for FIAs and RILAs, benefits of combining VA and RILA hedging and reserving under VM-21, current and future challenges with FIA reserving under VM-22, potential capital redundancy for FIAs, RILA interim values under AG 54, NAIC economic scenario reform, asset modeling, fund mapping and more!

Description: The cell and gene therapy marketplace is quickly evolving and continues to grow as a risk concern for governments, health plans, stop loss insurers and reinsurers. In this webinar, we discuss currently approved tissue, cell and gene therapies, the near-term pipeline, uptake considerations, case management processes, plan document and contract considerations, risk mitigation processes and programs, and network considerations.